Reasons Why mHealth Apps Matters for Pharma

The potential of mHealth solutions has been discussed for many years, but only recently, with the advent of the new smartphone application based mHealth model, have pharmaceutical companies begun to realize how mobile services might be instrumental in the development of exciting innovations in their own businesses.

The pharma market has always been cash-rich, as it needs to be given the investment required to continue the research and development behind the medical advances which have made such a difference to humanity. Nonetheless increasing pressure from regulators, thin pipelines and the patent cliff which has seen the rise of generics is a threat to continued prosperity. Innovative business models will help pharmaceutical manufacturers to remain competitive amidst these challenges.

Pharma companies should understand that mobile applications are an innovation area that matters. research2guidance presents 8 good reasons why smartphone apps matter to pharma:

1. Potential reach: Today the smartphone and mHealth markets are still small, but enormous growth rates will enable pharma companies to reach out to every 5th citizen on earth in 2015.

2. Differentiation: The potential for smartphone apps to support patient adherence and compliance makes them the ideal add-on for pharmaceutical products. Therapy supporting pharma applications for example will not only be providing a service, they will also differentiate their products from those offered by the competition.

3. Facilitate improved outcomes for patients taking the company's drugs: The success of a therapy is dependent upon correct compliance. Mobile applications provide the opportunity for pharmaceutical manufacturers to support patients by supplying applications that assist patients in achieving compliance, thereby improving patient outcomes.

4. Contemporary marketing: Physicians are already using smartphones and tablets to access healthcare related information. For pharmaceutical companies it would make sense to re-allocate marketing budgets spent on printed medical reference and CME programs to applications. They cost a fraction of what printed materials cost, are more innovative, represent a real value of less than $5, and fit into the regulatory framework in even the strictest systems.

5. Learn how patients use their medicine: Mobile applications offer a direct channel of communication between the manufacturer of a pharmaceutical product and the patient. Applications provide direct usage information, which can assist in understanding the usage habits of patients.

6. Saving costs: Smartphone apps have the potential to offer various cost-saving areas for pharmaceutical companies. Examples would be applications that support the exchange of results in medical trials, information on customers that would be useful to review before meeting with them, etc.

7. Improve relations with doctors: Apps are very personal tools, more so than websites of medical books. Visiting doctors is an essential but expensive aspect of pharma marketing, and the opportunity to connect directly with physicians by providing a useful app would be a good way to create new relationships with prescribing healthcare professionals.

8. Increasing revenue: Some mHealth solutions (like "patient monitoring" applications) might become the block-busters of the future, selling millions for a subscription of $10-$20 per month, even with the price for mHealth apps at between $5 and $10.

Please see research2guidance's Mobile Health Market Report 2010-2015 for more details and a detailed discussion on business opportunities for Pharma companies based on the new smartphone based mHealth market model.

About research2guidance
research2guidance is a Berlin-based market research company specialized in the mobile industry. The company's service offerings include comprehensive market studies, as well as bespoke research and consultancy. For more information, visit www.research2guidance.com.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...